NCT06854159
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Clinical trial condition
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Explore clinical trials studying Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
8 public trials
3 recruiting studies
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trial results
NCT06905509
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +23 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
NCT07042438
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT03210662
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +18 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT05075603
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
- Locations
-
- City of Hope Duarte, California, United States
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center Detroit, Michigan, United States
- Washington University in St. Louis St Louis, Missouri, United States
- Duke Cancer Institute Durham, North Carolina, United States
NCT04432506
- Conditions
- Hematologic Diseases, Hematologic Neoplasms, Hematopoietic and Lymphoid Cell Neoplasm, +20 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +30 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT05025800
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States